Perioperative management of patients on clopidogrel (Plavix) undergoing major lung resection

Mimi Ceppa, Ian J. Welsby, Tracy Y. Wang, Mark W. Onaitis, Betty C. Tong, David H. Harpole, Thomas A. D'Amico, Mark F. Berry

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Background: Management of patients requiring antiplatelet therapy with clopidogrel (Plavix) and major lung resection must balance the risks of bleeding and cardiovascular events. We reviewed our experience with patients treated with clopidogrel perioperatively to examine outcomes, including results of a new strategy for high-risk patients. Methods: Patients who underwent major lung resection and received perioperative clopidogrel between January 2005 and September 2010 were reviewed. Initially, clopidogrel management consisted of discontinuation approximately 5 days before surgery and resumption immediately after surgery. After July 2010, high-risk patients (drug-eluting coronary stent placement within prior year or previous coronary event after clopidogrel discontinuation) were admitted 2 to 3 days preoperatively and bridged with the intravenous glycoprotein IIb/IIIa receptor inhibitor eptifibatide (Integrilin) according to a multidisciplinary cardiology/anesthesiology/thoracic surgery protocol. Outcomes were compared with control patients (matched for preoperative risk factors and extent of pulmonary resection) who did not receive perioperative clopidogrel. Results: Fifty-four patients who had major lung resection between January 2005 and September 2010 and received clopidogrel perioperatively were matched with 108 control subjects. Both groups had similar mortality, postoperative length of stay, and no differences in the rates of perioperative transfusions, reoperations for bleeding, myocardial infarctions, and strokes. Seven of the 54 clopidogrel patients were admitted preoperatively for an eptifibatide bridge. Two of these patients received perioperative transfusions, but there were no deaths, reoperations, myocardial infarctions, or stroke. Conclusions: Patients taking clopidogrel can safely undergo major lung resection. Treatment with an eptifibatide bridge may minimize the risk of cardiovascular events in higher risk patients.

Original languageEnglish (US)
Pages (from-to)1971-1976
Number of pages6
JournalAnnals of Thoracic Surgery
Volume92
Issue number6
DOIs
StatePublished - Dec 2011
Externally publishedYes

Fingerprint

clopidogrel
Lung
Reoperation
Stroke
Myocardial Infarction
Hemorrhage

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery
  • Pulmonary and Respiratory Medicine

Cite this

Ceppa, M., Welsby, I. J., Wang, T. Y., Onaitis, M. W., Tong, B. C., Harpole, D. H., ... Berry, M. F. (2011). Perioperative management of patients on clopidogrel (Plavix) undergoing major lung resection. Annals of Thoracic Surgery, 92(6), 1971-1976. https://doi.org/10.1016/j.athoracsur.2011.07.052

Perioperative management of patients on clopidogrel (Plavix) undergoing major lung resection. / Ceppa, Mimi; Welsby, Ian J.; Wang, Tracy Y.; Onaitis, Mark W.; Tong, Betty C.; Harpole, David H.; D'Amico, Thomas A.; Berry, Mark F.

In: Annals of Thoracic Surgery, Vol. 92, No. 6, 12.2011, p. 1971-1976.

Research output: Contribution to journalArticle

Ceppa, M, Welsby, IJ, Wang, TY, Onaitis, MW, Tong, BC, Harpole, DH, D'Amico, TA & Berry, MF 2011, 'Perioperative management of patients on clopidogrel (Plavix) undergoing major lung resection', Annals of Thoracic Surgery, vol. 92, no. 6, pp. 1971-1976. https://doi.org/10.1016/j.athoracsur.2011.07.052
Ceppa, Mimi ; Welsby, Ian J. ; Wang, Tracy Y. ; Onaitis, Mark W. ; Tong, Betty C. ; Harpole, David H. ; D'Amico, Thomas A. ; Berry, Mark F. / Perioperative management of patients on clopidogrel (Plavix) undergoing major lung resection. In: Annals of Thoracic Surgery. 2011 ; Vol. 92, No. 6. pp. 1971-1976.
@article{a8f47790c3f04fd19992af3d311da2a5,
title = "Perioperative management of patients on clopidogrel (Plavix) undergoing major lung resection",
abstract = "Background: Management of patients requiring antiplatelet therapy with clopidogrel (Plavix) and major lung resection must balance the risks of bleeding and cardiovascular events. We reviewed our experience with patients treated with clopidogrel perioperatively to examine outcomes, including results of a new strategy for high-risk patients. Methods: Patients who underwent major lung resection and received perioperative clopidogrel between January 2005 and September 2010 were reviewed. Initially, clopidogrel management consisted of discontinuation approximately 5 days before surgery and resumption immediately after surgery. After July 2010, high-risk patients (drug-eluting coronary stent placement within prior year or previous coronary event after clopidogrel discontinuation) were admitted 2 to 3 days preoperatively and bridged with the intravenous glycoprotein IIb/IIIa receptor inhibitor eptifibatide (Integrilin) according to a multidisciplinary cardiology/anesthesiology/thoracic surgery protocol. Outcomes were compared with control patients (matched for preoperative risk factors and extent of pulmonary resection) who did not receive perioperative clopidogrel. Results: Fifty-four patients who had major lung resection between January 2005 and September 2010 and received clopidogrel perioperatively were matched with 108 control subjects. Both groups had similar mortality, postoperative length of stay, and no differences in the rates of perioperative transfusions, reoperations for bleeding, myocardial infarctions, and strokes. Seven of the 54 clopidogrel patients were admitted preoperatively for an eptifibatide bridge. Two of these patients received perioperative transfusions, but there were no deaths, reoperations, myocardial infarctions, or stroke. Conclusions: Patients taking clopidogrel can safely undergo major lung resection. Treatment with an eptifibatide bridge may minimize the risk of cardiovascular events in higher risk patients.",
author = "Mimi Ceppa and Welsby, {Ian J.} and Wang, {Tracy Y.} and Onaitis, {Mark W.} and Tong, {Betty C.} and Harpole, {David H.} and D'Amico, {Thomas A.} and Berry, {Mark F.}",
year = "2011",
month = "12",
doi = "10.1016/j.athoracsur.2011.07.052",
language = "English (US)",
volume = "92",
pages = "1971--1976",
journal = "Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "Elsevier USA",
number = "6",

}

TY - JOUR

T1 - Perioperative management of patients on clopidogrel (Plavix) undergoing major lung resection

AU - Ceppa, Mimi

AU - Welsby, Ian J.

AU - Wang, Tracy Y.

AU - Onaitis, Mark W.

AU - Tong, Betty C.

AU - Harpole, David H.

AU - D'Amico, Thomas A.

AU - Berry, Mark F.

PY - 2011/12

Y1 - 2011/12

N2 - Background: Management of patients requiring antiplatelet therapy with clopidogrel (Plavix) and major lung resection must balance the risks of bleeding and cardiovascular events. We reviewed our experience with patients treated with clopidogrel perioperatively to examine outcomes, including results of a new strategy for high-risk patients. Methods: Patients who underwent major lung resection and received perioperative clopidogrel between January 2005 and September 2010 were reviewed. Initially, clopidogrel management consisted of discontinuation approximately 5 days before surgery and resumption immediately after surgery. After July 2010, high-risk patients (drug-eluting coronary stent placement within prior year or previous coronary event after clopidogrel discontinuation) were admitted 2 to 3 days preoperatively and bridged with the intravenous glycoprotein IIb/IIIa receptor inhibitor eptifibatide (Integrilin) according to a multidisciplinary cardiology/anesthesiology/thoracic surgery protocol. Outcomes were compared with control patients (matched for preoperative risk factors and extent of pulmonary resection) who did not receive perioperative clopidogrel. Results: Fifty-four patients who had major lung resection between January 2005 and September 2010 and received clopidogrel perioperatively were matched with 108 control subjects. Both groups had similar mortality, postoperative length of stay, and no differences in the rates of perioperative transfusions, reoperations for bleeding, myocardial infarctions, and strokes. Seven of the 54 clopidogrel patients were admitted preoperatively for an eptifibatide bridge. Two of these patients received perioperative transfusions, but there were no deaths, reoperations, myocardial infarctions, or stroke. Conclusions: Patients taking clopidogrel can safely undergo major lung resection. Treatment with an eptifibatide bridge may minimize the risk of cardiovascular events in higher risk patients.

AB - Background: Management of patients requiring antiplatelet therapy with clopidogrel (Plavix) and major lung resection must balance the risks of bleeding and cardiovascular events. We reviewed our experience with patients treated with clopidogrel perioperatively to examine outcomes, including results of a new strategy for high-risk patients. Methods: Patients who underwent major lung resection and received perioperative clopidogrel between January 2005 and September 2010 were reviewed. Initially, clopidogrel management consisted of discontinuation approximately 5 days before surgery and resumption immediately after surgery. After July 2010, high-risk patients (drug-eluting coronary stent placement within prior year or previous coronary event after clopidogrel discontinuation) were admitted 2 to 3 days preoperatively and bridged with the intravenous glycoprotein IIb/IIIa receptor inhibitor eptifibatide (Integrilin) according to a multidisciplinary cardiology/anesthesiology/thoracic surgery protocol. Outcomes were compared with control patients (matched for preoperative risk factors and extent of pulmonary resection) who did not receive perioperative clopidogrel. Results: Fifty-four patients who had major lung resection between January 2005 and September 2010 and received clopidogrel perioperatively were matched with 108 control subjects. Both groups had similar mortality, postoperative length of stay, and no differences in the rates of perioperative transfusions, reoperations for bleeding, myocardial infarctions, and strokes. Seven of the 54 clopidogrel patients were admitted preoperatively for an eptifibatide bridge. Two of these patients received perioperative transfusions, but there were no deaths, reoperations, myocardial infarctions, or stroke. Conclusions: Patients taking clopidogrel can safely undergo major lung resection. Treatment with an eptifibatide bridge may minimize the risk of cardiovascular events in higher risk patients.

UR - http://www.scopus.com/inward/record.url?scp=81855185030&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81855185030&partnerID=8YFLogxK

U2 - 10.1016/j.athoracsur.2011.07.052

DO - 10.1016/j.athoracsur.2011.07.052

M3 - Article

C2 - 21978871

AN - SCOPUS:81855185030

VL - 92

SP - 1971

EP - 1976

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

SN - 0003-4975

IS - 6

ER -